KRAS and colonic neoplasm: Similar results were observed in the activating KRAS-mutant colon cancer cell line HCT116, where braftide reduced the CDC37–RAF interaction at lower doses than in HEK293 cells, suggesting this effect is not cell line specific (Fig. S1, A–E).